PVCs are common, occurring in 40-75% of the general population on Holter monitoring. While traditionally thought to be benign without structural heart disease, they represent an increased risk of sudden death in patients with conditions like ischemic heart disease. The frequency and complexity of PVCs is associated with increased mortality in these patients. Implantable cardioverter defibrillators are indicated for those with nonsustained ventricular tachycardia due to prior myocardial infarction and left ventricular ejection fraction ≤40% who are inducible for sustained ventricular arrhythmias on electrophysiological study. However, for patients with congestive heart failure, PVCs do not provide significant prognostic value beyond clinical variables. The concept of PVC-induced
This document discusses perioperative dysrhythmias. It begins by defining dysrhythmias and noting they represent an important cause of complications during surgery. While most are benign, some can be lethal or symptomatic. The document then discusses the incidence, which is seen in 70.2% of patients undergoing general anesthesia and varies depending on surgery type and monitoring. It provides details on the mechanisms, causes, and types of perioperative dysrhythmias, as well as their presentation, treatment, and contributing risk factors.
This document discusses the current concepts of anaesthesia for off-pump coronary artery bypass grafting (OPCAB). It begins with definitions of OPCAB and discusses its historical aspects. It then compares OPCAB to on-pump coronary artery bypass grafting and lists the goals of anaesthetic management for OPCAB. The document outlines considerations for preoperative assessment, induction, intraoperative management including hemodynamics, myocardial protection and postoperative/ICU management. It also discusses fast-track anesthesia and postoperative pain management.
Perioperative Care of the Cardiac Surgery Patient
This document outlines key aspects of perioperative care for cardiac surgery patients, including:
1) Preoperative evaluation to assess risk factors and optimize medical conditions;
2) Intraoperative management focusing on organ protection and hemodynamic optimization;
3) Postoperative care in the ICU addressing common complications like arrhythmias, bleeding, and pulmonary issues.
anaesthetic management of cardiac patients for non cardiac surgerydr tushar chokshi
The document discusses the benefits of exercise for mental health. It states that regular exercise can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that make a person feel happier and more relaxed and can help prevent mental illness.
Chronic kidney disease is defined as kidney damage or decreased kidney function (GFR <60mL/min/1.73m^2) for more than 3 months. It is staged based on GFR from stage 1 to 5. Major causes include diabetes and hypertension. Patients experience cardiovascular, respiratory, immune, electrolyte, gastrointestinal, endocrine, hematological, neurological and acid-base abnormalities due to decreased kidney function. Anesthesia management focuses on optimizing fluid, acid-base, electrolyte and hemodynamic status as well as modifying dosages based on creatinine clearance. Regional techniques may be used but prolonged bleeding time is a contraindication.
The document discusses strategies for re-establishing myocardial reperfusion in patients experiencing acute myocardial infarction (AMI) through either mechanical (percutaneous coronary intervention (PCI)) or pharmacological (thrombolytic agents) means. It emphasizes that time is critical and outlines aims to prevent death, limit myocardial damage, and minimize patient discomfort through early reperfusion before irreversible damage occurs. The rationale is presented for reducing time to treatment through public education, emergency department protocols, rapid diagnostics, and pre-hospital thrombolysis.
2022 ESC Guidelines Non Cardiac Surgery.pptxAyman Azoz
The document discusses the benefits of exercise for both physical and mental health. Regular exercise can improve cardiovascular health, reduce symptoms of depression and anxiety, enhance mood, and boost brain function. Staying physically active aims to strengthen the body and mind.
This document discusses perioperative dysrhythmias. It begins by defining dysrhythmias and noting they represent an important cause of complications during surgery. While most are benign, some can be lethal or symptomatic. The document then discusses the incidence, which is seen in 70.2% of patients undergoing general anesthesia and varies depending on surgery type and monitoring. It provides details on the mechanisms, causes, and types of perioperative dysrhythmias, as well as their presentation, treatment, and contributing risk factors.
This document discusses the current concepts of anaesthesia for off-pump coronary artery bypass grafting (OPCAB). It begins with definitions of OPCAB and discusses its historical aspects. It then compares OPCAB to on-pump coronary artery bypass grafting and lists the goals of anaesthetic management for OPCAB. The document outlines considerations for preoperative assessment, induction, intraoperative management including hemodynamics, myocardial protection and postoperative/ICU management. It also discusses fast-track anesthesia and postoperative pain management.
Perioperative Care of the Cardiac Surgery Patient
This document outlines key aspects of perioperative care for cardiac surgery patients, including:
1) Preoperative evaluation to assess risk factors and optimize medical conditions;
2) Intraoperative management focusing on organ protection and hemodynamic optimization;
3) Postoperative care in the ICU addressing common complications like arrhythmias, bleeding, and pulmonary issues.
anaesthetic management of cardiac patients for non cardiac surgerydr tushar chokshi
The document discusses the benefits of exercise for mental health. It states that regular exercise can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that make a person feel happier and more relaxed and can help prevent mental illness.
Chronic kidney disease is defined as kidney damage or decreased kidney function (GFR <60mL/min/1.73m^2) for more than 3 months. It is staged based on GFR from stage 1 to 5. Major causes include diabetes and hypertension. Patients experience cardiovascular, respiratory, immune, electrolyte, gastrointestinal, endocrine, hematological, neurological and acid-base abnormalities due to decreased kidney function. Anesthesia management focuses on optimizing fluid, acid-base, electrolyte and hemodynamic status as well as modifying dosages based on creatinine clearance. Regional techniques may be used but prolonged bleeding time is a contraindication.
The document discusses strategies for re-establishing myocardial reperfusion in patients experiencing acute myocardial infarction (AMI) through either mechanical (percutaneous coronary intervention (PCI)) or pharmacological (thrombolytic agents) means. It emphasizes that time is critical and outlines aims to prevent death, limit myocardial damage, and minimize patient discomfort through early reperfusion before irreversible damage occurs. The rationale is presented for reducing time to treatment through public education, emergency department protocols, rapid diagnostics, and pre-hospital thrombolysis.
2022 ESC Guidelines Non Cardiac Surgery.pptxAyman Azoz
The document discusses the benefits of exercise for both physical and mental health. Regular exercise can improve cardiovascular health, reduce symptoms of depression and anxiety, enhance mood, and boost brain function. Staying physically active aims to strengthen the body and mind.
1. Aortic regurgitation occurs when blood leaks backwards from the aorta into the left ventricle during diastole due to failure of the aortic valve leaflets to coapt properly.
2. It can be acute, caused by things like infective endocarditis or aortic dissection, or chronic, caused by conditions like bicuspid aortic valve or hypertension.
3. Chronic AR is often well-tolerated for years as the left ventricle dilates and hypertrophies to accommodate the increased volume, but acute AR can rapidly lead to heart failure and shock if not emergently treated.
Fluid responsiveness in critically ill patientsUbaidur Rahaman
This document discusses fluid responsiveness in critically ill patients. It begins by defining fluid responsiveness as an increase in cardiac index after fluid infusion. It then describes three scenarios involving fluid resuscitation: patients with acute blood or fluid loss requiring immediate resuscitation, patients with suspected septic shock where early goal-directed therapy with fluids is important, and ICU patients who have already received fluids and their fluid responsiveness needs to be assessed. The document discusses various methods of assessing preload and preload dependence, including filling pressures, volumes, respiratory variations in inferior vena cava diameter, inspiratory drops in right atrial pressure, and predicting responsiveness through respiratory variations in parameters related to cardiac index. It emphasizes that preload alone
This document provides guidelines for perioperative cardiovascular evaluation and management for patients undergoing non-cardiac surgery. It discusses preoperative clinical evaluation, testing, management of specific cardiovascular conditions, supplemental evaluation like ECG and stress testing, considerations for patients with prior coronary revascularization, perioperative medical therapy, intraoperative management, postoperative surveillance and long-term management. The document provides a stepwise approach and recommendations for evaluation and treatment of cardiovascular issues in the perioperative period.
Sepsis and septic shock guidelines 2021. part 1MEEQAT HOSPITAL
1. Sepsis is a critical imbalance between oxygen supply and demand that can affect any system. Serum lactate levels rise in response to tissue hypoxia and higher levels correlate with poorer outcomes.
2. Guidelines recommend screening high-risk patients for sepsis and using standard treatment protocols. Blood lactate should be measured in suspected cases and treatment begun immediately.
3. Fluid resuscitation of at least 30mL/kg should begin within 3 hours, guided by dynamic measures over static parameters alone. Antimicrobial therapy should also begin immediately or within 1-3 hours depending on risk level and presence of shock.
Post-Cardiac Arrest Syndrome:
Epidemiology, Pathophysiology, Treatment, and Prognostication
A Consensus Statement From the International Liaison Committee on Resuscitation
Circulation. 2008;118:2452-2483
This document provides an overview of arrhythmias that may present in the intensive care unit (ICU) with a focus on atrial fibrillation, wide complex tachycardia, bradycardia, and supraventricular tachycardia. It discusses approaches to determining whether arrhythmias require rate or rhythm control and outlines treatment strategies including pharmacological and electrical cardioversion. Guidelines for determining the need for anticoagulation based on a patient's CHADS2-VASc score are also reviewed.
Renal replacement therapy (RRT) refers to life-supporting treatments for renal failure and includes hemodialysis, peritoneal dialysis, and continuous renal replacement therapy. The choice of RRT depends on factors like the patient's cardiovascular status, availability of resources, and clinical considerations. Common complications include those related to vascular access and electrolyte imbalances. RRT aims to correct fluid overload, metabolic abnormalities, and remove waste through diffusion or convection.
Critical Care Summit Egypt 2015 Common Arrhythmias in the ICUDr.Mahmoud Abbas
Lecture presented by Dr Khaled Farouk at Egyptian Critical Care Summit 2015, the leading ICU event and medical exhibition in Egypt. www.criticalcareegypt.com
diastolic heart failure an enemy in cardiologyrahul arora
This document discusses diastolic heart failure (HFpEF). It outlines how the definition of HFpEF has evolved over time to include structural heart abnormalities and elevated biomarkers in addition to preserved ejection fraction and diastolic dysfunction. HFpEF may represent multiple disease entities rather than a single disease. Clinical trials of HFpEF have generally failed due to heterogeneous patient populations and interventions not targeting specific pathophysiologies. The document proposes a more systematic approach to diagnosing and classifying HFpEF patients to identify subgroups that may benefit more from certain therapies. It also presents a clinical case of a patient with HFpEF and discusses guidelines for managing their symptoms and risk factors.
Perioperative cardiovascular assessment of patients undergoing noncardiac sur...kazi alam nowaz
Perioperative cardiovascular assessment is necessary for patients undergoing noncardiac surgery to evaluate medical status, cardiac risks, and recommend strategies to improve short and long term outcomes. Surgeries are stratified as low, intermediate, or high risk depending on the procedure. For patients at elevated risk, further testing like stress testing may be considered to guide management. Guidelines recommend continuing medications like beta blockers and statins perioperatively, as well as delaying surgery for patients with stents based on type. The timing and risks of surgery must be weighed based on a patient's cardiovascular condition and procedure.
No reflow and slow flow phenomenon during pcirahul arora
This document discusses strategies and prevention of slow flow and no-reflow phenomenon during percutaneous coronary intervention (PCI). It defines no-reflow as inadequate myocardial perfusion through a coronary artery without mechanical obstruction. No-reflow occurs in 8-11% of primary PCIs and is associated with worse clinical outcomes. The pathophysiology involves distal embolization, ischemic injury, reperfusion injury, and individual patient susceptibility. Preventing no-reflow requires reducing thrombus burden, ischemia time, reperfusion injury through anti-inflammatory drugs, and addressing risk factors like diabetes.
pre op evaluation of cardiac pts for non-cardiac surgeryVkas Subedi
This document discusses the preoperative evaluation of cardiac patients undergoing non-cardiac surgery. It notes that 1-5% of unselected patients experience perioperative cardiac morbidity, and outlines the goals of pre-op evaluation as defining risks, determining if further testing is beneficial, planning anesthesia appropriately, and considering peri-op beta blockade or other therapies. It discusses evaluating patients' history, symptoms, physical exam findings, and using risk indices to stratify cardiac risk. Higher risk factors include recent MI, heart failure, significant arrhythmias or valvular disease. The document provides recommendations for further testing and treatment based on a patient's functional status and cardiac conditions.
The document discusses the anesthetic management of patients undergoing treatment for cerebral aneurysms, including definitions, epidemiology, presentation, diagnosis, management of vasospasm, intracranial pressure, pre-operative assessment and testing, and radiological procedures such as coiling of aneurysms. Precise management of hemodynamics, fluid balance, and respiratory status is important due to the risks of re-bleeding, cerebral ischemia, and impaired autoregulation in these patients.
This document discusses anticoagulation and hemostasis during cardiopulmonary bypass. It covers normal coagulation pathways, the use of heparin for anticoagulation during bypass, and protamine for reversing the effects of heparin afterwards. Complications from heparin like heparin-induced thrombocytopenia and alternatives to heparin and protamine are also reviewed. Maintaining the delicate balance of anticoagulation during bypass and restoring hemostasis afterwards is an important consideration in cardiac surgery.
This document discusses the relationship between heart and lung function and the interaction between intrathoracic pressures, lung volumes, and blood flow. It begins by explaining that the cardiovascular and pulmonary systems function to link metabolizing cells to oxygen sources. It then discusses how intrathoracic and intramural pressures impact blood flow through collapsible tubes based on principles of fluid dynamics. Changes in surrounding pressures, such as pleural or pericardial pressure, can impact lung volumes, cardiac preload and afterload, and venous return. Understanding these complex interactions is important for critical care.
The document discusses various types of cardiac arrhythmias including their definitions, causes, clinical manifestations and management. It describes normal sinus rhythm and defines arrhythmias as any change from the normal heart rhythm. Common arrhythmias discussed include sinus tachycardia, sinus bradycardia, premature atrial complexes, premature ventricular complexes, atrial flutter, atrial fibrillation and ventricular tachycardia. It provides EKG images to demonstrate the different arrhythmias and compares characteristics of supraventricular and ventricular arrhythmias. Causes, clinical significance and treatment approaches for different arrhythmias are also summarized.
The document summarizes updated guidelines from the 41th Society of Critical Care Medicine Meeting for treating sepsis. Key changes include recommending crystalloids like saline for initial fluid resuscitation; using norepinephrine as the first choice vasopressor; considering corticosteroids for refractory shock; using higher PEEP and recruitment maneuvers for ARDS; and considering procalcitonin to determine if antibiotics can be stopped. The Surviving Sepsis guidelines were previously criticized for being funded primarily by Eli Lilly without disclosure.
Anesthetic considerations for kidney transplant in an adult Eko indra
Kidney transplantation involves attaching a donor kidney to replace diseased kidneys. Survival is better after transplantation than dialysis. The first human kidney transplant was in 1933 in Ukraine but the recipient died after 48 hours. In Indonesia, the first transplant was in 1977. Risks include graft dysfunction, rejection, and technical complications like thrombosis. Anesthesia aims to prevent renal insults and maintain perfusion through fluid management and hemodynamics monitoring.
PREMATURE VENTRICULAR COMPLEX: DIAGNOSIS AND MANAGEMENTajay pratap singh
This document discusses premature ventricular complexes (PVCs) and catheter ablation for treating PVCs. It defines PVCs as early ventricular depolarizations that do not necessarily lead to contractions. Common causes of PVCs include electrolyte abnormalities, ischemia, and cardiomyopathies. The prevalence of PVCs increases with age and longer monitoring. Frequent PVCs can impair left ventricular function and cause a PVC-induced cardiomyopathy. Catheter ablation is an effective treatment for eliminating PVCs when medications are ineffective or not tolerated.
Ventricular fibrillation (VF) is a life-threatening heart rhythm disorder that usually results in cardiac arrest if not treated promptly. It occurs when the lower chambers of the heart beat in an uncoordinated, chaotic fashion, preventing the heart from pumping blood effectively. VF accounts for about 300,000 deaths per year in the United States, making it the leading cause of sudden cardiac death. It is commonly caused by coronary artery disease and often presents as the first sign of a heart attack. Prompt treatment with cardiopulmonary resuscitation and defibrillation can help restore a normal heart rhythm and prevent death from VF in some cases.
1. Aortic regurgitation occurs when blood leaks backwards from the aorta into the left ventricle during diastole due to failure of the aortic valve leaflets to coapt properly.
2. It can be acute, caused by things like infective endocarditis or aortic dissection, or chronic, caused by conditions like bicuspid aortic valve or hypertension.
3. Chronic AR is often well-tolerated for years as the left ventricle dilates and hypertrophies to accommodate the increased volume, but acute AR can rapidly lead to heart failure and shock if not emergently treated.
Fluid responsiveness in critically ill patientsUbaidur Rahaman
This document discusses fluid responsiveness in critically ill patients. It begins by defining fluid responsiveness as an increase in cardiac index after fluid infusion. It then describes three scenarios involving fluid resuscitation: patients with acute blood or fluid loss requiring immediate resuscitation, patients with suspected septic shock where early goal-directed therapy with fluids is important, and ICU patients who have already received fluids and their fluid responsiveness needs to be assessed. The document discusses various methods of assessing preload and preload dependence, including filling pressures, volumes, respiratory variations in inferior vena cava diameter, inspiratory drops in right atrial pressure, and predicting responsiveness through respiratory variations in parameters related to cardiac index. It emphasizes that preload alone
This document provides guidelines for perioperative cardiovascular evaluation and management for patients undergoing non-cardiac surgery. It discusses preoperative clinical evaluation, testing, management of specific cardiovascular conditions, supplemental evaluation like ECG and stress testing, considerations for patients with prior coronary revascularization, perioperative medical therapy, intraoperative management, postoperative surveillance and long-term management. The document provides a stepwise approach and recommendations for evaluation and treatment of cardiovascular issues in the perioperative period.
Sepsis and septic shock guidelines 2021. part 1MEEQAT HOSPITAL
1. Sepsis is a critical imbalance between oxygen supply and demand that can affect any system. Serum lactate levels rise in response to tissue hypoxia and higher levels correlate with poorer outcomes.
2. Guidelines recommend screening high-risk patients for sepsis and using standard treatment protocols. Blood lactate should be measured in suspected cases and treatment begun immediately.
3. Fluid resuscitation of at least 30mL/kg should begin within 3 hours, guided by dynamic measures over static parameters alone. Antimicrobial therapy should also begin immediately or within 1-3 hours depending on risk level and presence of shock.
Post-Cardiac Arrest Syndrome:
Epidemiology, Pathophysiology, Treatment, and Prognostication
A Consensus Statement From the International Liaison Committee on Resuscitation
Circulation. 2008;118:2452-2483
This document provides an overview of arrhythmias that may present in the intensive care unit (ICU) with a focus on atrial fibrillation, wide complex tachycardia, bradycardia, and supraventricular tachycardia. It discusses approaches to determining whether arrhythmias require rate or rhythm control and outlines treatment strategies including pharmacological and electrical cardioversion. Guidelines for determining the need for anticoagulation based on a patient's CHADS2-VASc score are also reviewed.
Renal replacement therapy (RRT) refers to life-supporting treatments for renal failure and includes hemodialysis, peritoneal dialysis, and continuous renal replacement therapy. The choice of RRT depends on factors like the patient's cardiovascular status, availability of resources, and clinical considerations. Common complications include those related to vascular access and electrolyte imbalances. RRT aims to correct fluid overload, metabolic abnormalities, and remove waste through diffusion or convection.
Critical Care Summit Egypt 2015 Common Arrhythmias in the ICUDr.Mahmoud Abbas
Lecture presented by Dr Khaled Farouk at Egyptian Critical Care Summit 2015, the leading ICU event and medical exhibition in Egypt. www.criticalcareegypt.com
diastolic heart failure an enemy in cardiologyrahul arora
This document discusses diastolic heart failure (HFpEF). It outlines how the definition of HFpEF has evolved over time to include structural heart abnormalities and elevated biomarkers in addition to preserved ejection fraction and diastolic dysfunction. HFpEF may represent multiple disease entities rather than a single disease. Clinical trials of HFpEF have generally failed due to heterogeneous patient populations and interventions not targeting specific pathophysiologies. The document proposes a more systematic approach to diagnosing and classifying HFpEF patients to identify subgroups that may benefit more from certain therapies. It also presents a clinical case of a patient with HFpEF and discusses guidelines for managing their symptoms and risk factors.
Perioperative cardiovascular assessment of patients undergoing noncardiac sur...kazi alam nowaz
Perioperative cardiovascular assessment is necessary for patients undergoing noncardiac surgery to evaluate medical status, cardiac risks, and recommend strategies to improve short and long term outcomes. Surgeries are stratified as low, intermediate, or high risk depending on the procedure. For patients at elevated risk, further testing like stress testing may be considered to guide management. Guidelines recommend continuing medications like beta blockers and statins perioperatively, as well as delaying surgery for patients with stents based on type. The timing and risks of surgery must be weighed based on a patient's cardiovascular condition and procedure.
No reflow and slow flow phenomenon during pcirahul arora
This document discusses strategies and prevention of slow flow and no-reflow phenomenon during percutaneous coronary intervention (PCI). It defines no-reflow as inadequate myocardial perfusion through a coronary artery without mechanical obstruction. No-reflow occurs in 8-11% of primary PCIs and is associated with worse clinical outcomes. The pathophysiology involves distal embolization, ischemic injury, reperfusion injury, and individual patient susceptibility. Preventing no-reflow requires reducing thrombus burden, ischemia time, reperfusion injury through anti-inflammatory drugs, and addressing risk factors like diabetes.
pre op evaluation of cardiac pts for non-cardiac surgeryVkas Subedi
This document discusses the preoperative evaluation of cardiac patients undergoing non-cardiac surgery. It notes that 1-5% of unselected patients experience perioperative cardiac morbidity, and outlines the goals of pre-op evaluation as defining risks, determining if further testing is beneficial, planning anesthesia appropriately, and considering peri-op beta blockade or other therapies. It discusses evaluating patients' history, symptoms, physical exam findings, and using risk indices to stratify cardiac risk. Higher risk factors include recent MI, heart failure, significant arrhythmias or valvular disease. The document provides recommendations for further testing and treatment based on a patient's functional status and cardiac conditions.
The document discusses the anesthetic management of patients undergoing treatment for cerebral aneurysms, including definitions, epidemiology, presentation, diagnosis, management of vasospasm, intracranial pressure, pre-operative assessment and testing, and radiological procedures such as coiling of aneurysms. Precise management of hemodynamics, fluid balance, and respiratory status is important due to the risks of re-bleeding, cerebral ischemia, and impaired autoregulation in these patients.
This document discusses anticoagulation and hemostasis during cardiopulmonary bypass. It covers normal coagulation pathways, the use of heparin for anticoagulation during bypass, and protamine for reversing the effects of heparin afterwards. Complications from heparin like heparin-induced thrombocytopenia and alternatives to heparin and protamine are also reviewed. Maintaining the delicate balance of anticoagulation during bypass and restoring hemostasis afterwards is an important consideration in cardiac surgery.
This document discusses the relationship between heart and lung function and the interaction between intrathoracic pressures, lung volumes, and blood flow. It begins by explaining that the cardiovascular and pulmonary systems function to link metabolizing cells to oxygen sources. It then discusses how intrathoracic and intramural pressures impact blood flow through collapsible tubes based on principles of fluid dynamics. Changes in surrounding pressures, such as pleural or pericardial pressure, can impact lung volumes, cardiac preload and afterload, and venous return. Understanding these complex interactions is important for critical care.
The document discusses various types of cardiac arrhythmias including their definitions, causes, clinical manifestations and management. It describes normal sinus rhythm and defines arrhythmias as any change from the normal heart rhythm. Common arrhythmias discussed include sinus tachycardia, sinus bradycardia, premature atrial complexes, premature ventricular complexes, atrial flutter, atrial fibrillation and ventricular tachycardia. It provides EKG images to demonstrate the different arrhythmias and compares characteristics of supraventricular and ventricular arrhythmias. Causes, clinical significance and treatment approaches for different arrhythmias are also summarized.
The document summarizes updated guidelines from the 41th Society of Critical Care Medicine Meeting for treating sepsis. Key changes include recommending crystalloids like saline for initial fluid resuscitation; using norepinephrine as the first choice vasopressor; considering corticosteroids for refractory shock; using higher PEEP and recruitment maneuvers for ARDS; and considering procalcitonin to determine if antibiotics can be stopped. The Surviving Sepsis guidelines were previously criticized for being funded primarily by Eli Lilly without disclosure.
Anesthetic considerations for kidney transplant in an adult Eko indra
Kidney transplantation involves attaching a donor kidney to replace diseased kidneys. Survival is better after transplantation than dialysis. The first human kidney transplant was in 1933 in Ukraine but the recipient died after 48 hours. In Indonesia, the first transplant was in 1977. Risks include graft dysfunction, rejection, and technical complications like thrombosis. Anesthesia aims to prevent renal insults and maintain perfusion through fluid management and hemodynamics monitoring.
PREMATURE VENTRICULAR COMPLEX: DIAGNOSIS AND MANAGEMENTajay pratap singh
This document discusses premature ventricular complexes (PVCs) and catheter ablation for treating PVCs. It defines PVCs as early ventricular depolarizations that do not necessarily lead to contractions. Common causes of PVCs include electrolyte abnormalities, ischemia, and cardiomyopathies. The prevalence of PVCs increases with age and longer monitoring. Frequent PVCs can impair left ventricular function and cause a PVC-induced cardiomyopathy. Catheter ablation is an effective treatment for eliminating PVCs when medications are ineffective or not tolerated.
Ventricular fibrillation (VF) is a life-threatening heart rhythm disorder that usually results in cardiac arrest if not treated promptly. It occurs when the lower chambers of the heart beat in an uncoordinated, chaotic fashion, preventing the heart from pumping blood effectively. VF accounts for about 300,000 deaths per year in the United States, making it the leading cause of sudden cardiac death. It is commonly caused by coronary artery disease and often presents as the first sign of a heart attack. Prompt treatment with cardiopulmonary resuscitation and defibrillation can help restore a normal heart rhythm and prevent death from VF in some cases.
Prediction and Prevention in Sudden Cardiac DeathApollo Hospitals
This document discusses prediction and prevention of sudden cardiac death (SCD). It begins by stating that SCD is the most common cause of death worldwide, accounting for over 50% of cardiovascular deaths. The document then discusses various risk factors for SCD, including left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) functional class, electrocardiogram abnormalities like prolonged QRS duration and QT interval. It states that while LVEF <30-35% is the most consistent predictor of cardiac mortality, current risk stratification techniques lack sufficient predictive value to identify high-risk individuals. The document emphasizes the need for improved prediction and prevention strategies given the high mortality from SCD.
This document provides an overview of sudden cardiac death, including its definition, epidemiology, risk factors, etiologies, clinical features, management, and prevention. Some key points include:
- Sudden cardiac death is defined as natural death from cardiac causes within 1 hour of symptom onset. It accounts for about 50% of cardiovascular deaths.
- Risk factors include increasing age, male sex, coronary heart disease, smoking, elevated cholesterol, emotional stress, depression, low socioeconomic status, and left ventricular dysfunction.
- Transient factors like ischemia, electrolyte abnormalities, drugs, and autonomic influences can trigger lethal arrhythmias in those with underlying structural heart issues. Antiarrhythmic drugs in particular carry
The document discusses the continued importance and value of the electrocardiogram (ECG) for cardiologists. It summarizes several ways that analyzing the ECG can help identify patients at high risk for sudden cardiac death, diagnose cardiac conditions, and predict outcomes. For example, it describes how a prolonged QTc interval on the ECG is a risk factor for sudden cardiac death and how the presence and degree of left ventricular hypertrophy shown on an ECG can predict future heart failure and cardiovascular events. The document advocates that clinicians should continue utilizing the ECG as it provides vital diagnostic information to guide patient care and treatment decisions.
Sudden Cardiac Death and Chronic Kidney DiseaseShodhan Patel
Sudden cardiac death is responsible for about one fourth of all cause mortality in dialysis patients. In chronic kidney disease, factors like left ventricular hypertrophy, electrolyte shifts, inflammation, and divalent ion abnormalities predispose patients to arrhythmias and sudden cardiac death. The risks are further increased by comorbidities like ischemic heart disease, prolonged QT interval, iron overload, and sympathetic overactivity. Preventive strategies include optimizing volume control with frequent or nocturnal dialysis, treating hypertension and left ventricular hypertrophy with beta blockers or calcium channel blockers, and managing inflammation and mineral bone disorders.
This document provides an overview of carotid artery stenosis. It discusses the anatomy of the carotid arteries and how stenosis can increase the risk of stroke by reducing blood flow to the brain. Symptoms of stenosis range from transient ischemic attacks to full strokes, depending on the location and severity of the blockage. Imaging plays a key role in detecting and evaluating carotid artery stenosis. Treatment may involve medications, lifestyle changes, or carotid endarterectomy surgery to remove plaque buildup.
This document discusses anesthetic considerations for patients with advanced valvular heart disease undergoing noncardiac surgery. It begins by noting the increasing prevalence of valvular heart disease in the aging population. It then focuses on aortic stenosis, describing its epidemiology, causes, symptoms, pathophysiology and how the disease progresses. The key anesthetic considerations for patients with aortic stenosis are maintaining sinus rhythm, a slow heart rate, adequate preload and afterload to minimize the risk of myocardial ischemia due to the pathophysiology of the disease. Careful preoperative evaluation and perioperative management are important to optimize outcomes.
This document summarizes a research article that proposes a new hypothesis for studying sudden heart pathology. The authors suggest developing a new diagnostic test that can stress the heart's metabolic processes under normal and abnormal conditions locally within the heart tissue, rather than examining blood plasma. This could help prevent events like heart attacks, arrhythmias, and transplant failure by better understanding the heart's metabolic response under stress. Currently about 20% of sudden cardiac deaths are not explained by autopsy findings, so new testing of the heart's metabolic response directly may provide more insights into these cases. The authors believe translating diagnostic approaches from other medical fields could offer a novel perspective on phenomena in cardiology.
ARITMIE VENTRICOLARI NEI CONGENITI ADULTI: INDICAZIONI E TIMING DELL’ABLAZIONEpasqualevergara1
This document discusses risk stratification and management of ventricular arrhythmias in adults with congenital heart disease, particularly those with tetralogy of Fallot (ToF). It finds that ventricular tachycardia (VT) ablation is effective for treating VTs in ToF patients, with most VTs being fast and monomorphic. Risk factors for sudden cardiac death in ToF include prolonged QRS duration, ventricular dysfunction, nonsustained VT on Holter monitoring, and syncope. Cardiac MRI can identify predictors of death and sustained VT like right ventricular hypertrophy and fibrosis. Electrophysiological study can assess risk and guide decisions about implantable cardioverter defibrillator placement.
This document discusses cardioembolic stroke, which occurs when heart issues cause materials to enter the brain's blood vessels. Common causes include atrial fibrillation, heart failure, and mechanical heart valves. Diagnosis involves echocardiography and monitoring for embolic signals. Treatment depends on the specific heart condition but often includes anticoagulants to prevent clots. Anticoagulation reduces stroke risk from atrial fibrillation by 60-90% compared to placebo. Managing cardioembolic stroke risk requires identifying the underlying heart condition and addressing it with medications, surgery, or lifestyle changes.
Contemporary Perspectives on the Diagnosis and Management of Hypertrophic Car...asclepiuspdfs
Hypertrophic cardiomyopathy (HCM) is a cardiovascular disorder with genetic predisposition. The number of treatment modalities has grown in the contemporary era, with use of pharmacotherapy, device therapy, and surgical intervention, though with the relative paucity of data derived from randomized trials. Its clinical course and prognosis are relatively good. The ongoing quest is to establish the optimal treatment strategy in patients with HCM. This is of direct relevance in reducing the mortality burden associated with sudden cardiac death primarily secondary to dysrhythmias. This review summarizes the clinical features, course, and management of HCM. In particular, we highlight advances in cardiac magnetic resonance imaging assessment of HCM and how risk stratification criteria for suitability of implantable cardioverter defibrillators differ between continents.
1. A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by focal brain or retinal ischemia, with symptoms typically lasting less than one hour without evidence of acute infarction.
2. The risk of stroke is highest in the first few days after a TIA, with about a 10% risk of stroke in the first week and 15% risk within the first 90 days.
3. Evaluation of patients with suspected TIA involves detailed history, neurological exam, prognostic testing like the ABCD2 score, and investigations including blood tests, brain and vascular imaging to identify the cause and risk of future stroke.
The document proposes a new research hypothesis to better understand sudden heart pathology through innovative diagnostic methods. It suggests testing the heart's biochemical-metabolic status or pharmacological profile under normal and stressed conditions locally in the heart tissue, rather than just plasma, to help prevent unexpected cardiac events. While many diagnostic strategies currently exist, about 20% of sudden cardiac deaths still lack an identified abnormality. The authors believe new tests analyzing the heart's local performance under varying physiological stresses could provide more useful information to clarify pathological causes, especially in young patients where atherosclerosis is less common. This approach may help explain cases of sudden cardiac arrest in untrained individuals during vigorous exertion.
Carotid revascularization in cad patientsDIPAK PATADE
Carotid artery disease is common in patients with coronary artery disease undergoing coronary artery bypass grafting (CABG). The incidence of perioperative stroke after CABG is around 1.6-3.1%, with risks increased by factors like aortic atherosclerosis, atrial fibrillation, prior stroke, and carotid stenosis. Strokes are often embolic and occur during or soon after surgery. Asymptomatic carotid stenosis alone may not increase stroke risks significantly, but bilateral or recently symptomatic stenosis does. Careful screening and management of atherosclerotic risk factors can help reduce perioperative stroke risks in patients with coexisting carotid and coronary artery disease.
06 the anesthesia patient with acute coronary syndrome copiaUSACHCHSJ
This document discusses the management of patients with acute coronary syndrome (ACS) in the perioperative period. It begins with an overview of ACS, distinguishing between unstable angina, myocardial infarction without ST-segment elevation (NSTEMI), and myocardial infarction with ST-segment elevation (STEMI). It then reviews the diagnosis, pathophysiology, and standard treatment of ACS outside of surgery, including antiplatelet therapy, antithrombin therapy, and beta-blockade. The document indicates that the anesthesiologist must understand how ACS is typically treated to properly manage patients who present for surgery with ACS.
1) Acute myocardial infarction is irreversible necrosis of heart muscle caused by prolonged ischemia and can present as unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) or ST-elevation myocardial infarction (STEMI).
2) UA/NSTEMI is diagnosed based on symptoms of chest pain or discomfort and elevated cardiac biomarkers showing myocardial necrosis.
3) Treatment involves reducing myocardial oxygen demands, improving supply, and risk stratification to determine need for aggressive versus conservative management. High risk patients may receive early invasive procedures while low risk patients can be managed medically.
Cardioembolic cerebral infarction accounts for 14-30% of ischemic strokes. It has a high mortality rate compared to other stroke subtypes. Certain clinical features support a diagnosis of cardioembolic stroke, including sudden onset to maximal deficit within 5 minutes, decreased consciousness, Wernicke's or global aphasia without hemiparesis, onset during a Valsalva maneuver, and hemorrhagic transformation of the infarct. Lacunar presentations and multiple lacunar infarcts make a cardioembolic origin less likely. Echocardiography can identify potential cardiac sources of embolism.
The document discusses strategies for preventing thromboembolism in patients with atrial fibrillation. It describes various risk scoring systems used to estimate stroke risk, such as CHADS2 and CHA2DS2-VASc. It recommends oral anticoagulation for patients with a CHADS2 score of 2 or higher. While aspirin provides some protection, oral anticoagulants like warfarin are more effective at reducing stroke risk. Newer oral anticoagulants also provide benefit compared to warfarin. For patients who cannot take oral anticoagulants, aspirin plus clopidogrel may be considered despite higher bleeding risks.
Assessment of prosthetic valve functionSwapnil Garde
This document discusses the assessment of prosthetic valve function through various imaging modalities. It begins with an introduction to prosthetic valves and outlines topics to be covered, including classification of valve types. Evaluation methods like chest x-ray, fluoroscopy, echocardiography, and CT are described. Parameters assessed on each modality and guidelines for evaluation are provided. Complications of prosthetic valves and 3D imaging advances are also mentioned.
The document discusses various techniques for assessing myocardial viability, including stress echocardiography, single photon emission computed tomography (SPECT), positron emission tomography (PET), and cardiac magnetic resonance imaging (MRI). Stress echocardiography evaluates contractile reserve through techniques like dobutamine stress echocardiography. SPECT assesses viability by detecting thallium or technetium uptake, which relies on intact cell membranes. PET detects FDG uptake indicating active glucose metabolism. MRI evaluates viability through detection of late gadolinium enhancement, indicating scar tissue, and can also assess contractile reserve with stress MRI. A combined approach utilizing multiple techniques can provide complementary information on viability.
This document provides an overview of approaches to chronic total occlusion percutaneous coronary intervention (CTO PCI). It defines CTOs and discusses their prevalence. Key points include:
- Success rates for CTO PCI are over 90% currently due to improved techniques and tools.
- Imaging like angiography, CT angiography, and IVUS help plan procedures by assessing lesion characteristics and collateral circulation.
- The retrograde approach and antegrade dissection and re-entry are common techniques in addition to the standard antegrade wire escalation method.
- Scoring systems like the J-CTO and W-CTO scores can predict difficulty and likelihood of success to help determine approach.
- Careful planning including
Antithrombotic therapy in patients with atrialSwapnil Garde
- The optimal antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention poses challenges due to the need to balance risks of bleeding and thrombosis.
- New clinical trials have found that using a non-vitamin K oral anticoagulant (NOAC) along with a single antiplatelet drug reduces bleeding risks compared to the standard triple therapy of oral anticoagulant, aspirin, and clopidogrel, without increasing thrombotic risks.
- This expert consensus recommends generally using an NOAC over a vitamin K antagonist, along with single antiplatelet therapy, based on the trial results showing better safety outcomes with lower bleeding.
This document summarizes a seminar on the management of cardiac arrest and cardiac arrest survivors. It defines cardiac arrest and discusses mechanisms and causes. It reviews changes to CPR guidelines including a compression to ventilation ratio of 30:2. It discusses factors that affect blood flow during CPR and prognostic factors for poor outcomes. Management strategies are outlined for defibrillation, antiarrhythmic drugs, vasopressors, steroids and extracorporeal CPR. Adjuncts to CPR like oxygen support and monitoring techniques are also summarized.
Debate of opening non infarct related arteriesSwapnil Garde
This document discusses the debate around opening non-infarct related arteries (non-IRA) during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). It provides background on the higher mortality and reinfarction rates seen in patients with multi-vessel disease. It also summarizes several trials that have compared culprit-only PCI versus complete revascularization, with some trials like PRAMI and CvLPRIT finding lower event rates with complete revascularization, while others like CULPRIT-SHOCK found lower mortality and renal failure with culprit-only PCI in cardiogenic shock patients. The optimal strategy for managing non-IRA lesions during primary PCI for STEMI remains debated.
This document summarizes information about patent foramen ovale (PFO) closure procedures. It begins by describing a PFO and conditions it can be associated with like cryptogenic stroke. It then discusses devices used for closure like the Amplatzer PFO Occluder and the procedure. Risks include air embolism or device migration. The document also reviews trials that have evaluated PFO closure for stroke prevention. While some trials were negative, a meta-analysis showed a trend favoring closure, particularly in high-risk groups. Ongoing trials aim to provide more clarity around PFO closure benefits.
Pictorial and detailed description of patellar instability with sign and symptoms and how to diagnose , what investigations you should go with and how to approach with treatment options . I have presented this slide in my 2nd year junior residency in orthopedics at LLRM medical college Meerut and got good reviews for it
After getting it read you will definitely understand the topic.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
1. Current Concepts of Premature Ventricular Contractions
Min-Soo Ahn*
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
Premature ventricular contractions (PVCs) are early depolarizations of the myocardium originating in the ventricle.
PVCs are common with an estimated prevalence of 40% to 75% in the general population on 24- to 48-hour Holter
monitoring. Traditionally, they have been thought to be relatively benign in the absence of structural heart disease
but they represent increased risk of sudden death in structural heart disease. Especially in ischemic heart disease, the
frequency and complexity of PVCs is associated with mortality. Implantable cardioverter defibrillator therapy is in-
dicated in patients with nonsustained ventricular tachycardia (NSVT) due to prior myocardial infarction, left ven-
tricular ejection fraction less than or equal to 40%, and inducible ventricular fibrillation or sustained ventricular tachy-
cardia at electrophysiological study. In congestive heart failure, PVCs did not provide significant incremental prognostic
information beyond readily available clinical variables. Consequently, NSVT should not guide therapeutic
interventions. Recently, the concept of PVC-induced cardiomyopathy was proposed when pharmacological suppression
of PVCs in patients with presumed idiopathic dilated cardiomyopathy subsequently showed improved left ventricular
systolic dysfunction. For the treatment PVCs, it is important to consider underlying heart disease, the frequency of
the PVCs and the frequency and severity of symptoms.
Key Words: Premature ventricular contractions, Nonsustained ventricular tachycardia, Cardiomyopathy
Received: January 8, 2013, Accepted: January 14, 2013
*Corresponding author: Min-Soo Ahn
Department of Internal Medicine, Yonsei University Wonju College
of Medicine, 20 Ilsan-ro, Wonju, Gangwon-do 220-701, Republic of
Korea
Tel: 82-33-741-0917, Fax: 82-33-741-1219
E-mail: heartsaver@yonsei.ac.kr
Review Article Vol. 3, No. 1, 26-33
INTRODUCTION
Premature ventricular contractions (PVCs) are early de-
polarizations of the myocardium originating in the ventricle
(Fig. 1). PVCs are common with an estimated prevalence
of 1% to 4% in the general population on standard 12-lead
electrocardiography and between 40% and 75% of subjects
on 24- to 48-hour Holter monitoring [1,2]. Ventricular ec-
topic activity occurs in a wide variety of clinical settings
with a spectrum of clinical implications. They are often seen
in association with structural heart disease and represent in-
creased risk of sudden death, yet they are ubiquitous, even
in the absence of identifiable heart disease [3,4]. Traditio-
nally, they have been thought to be relatively benign in the
absence of structural heart disease [2,5]. Over the last dec-
ade, however, PVC-induced cardiomyopathy (CMP) has
been a subject of great interest and the evidence for this
entity is rapidly emerging. Appropriate clinical evaluation
and investigations are important in assessing patients with
PVCs so that effective treatment can be targeted when
necessary. This article discusses the current knowledge and
practice in this commonly encountered clinical cardiological
problem.
PROGNOSIS OF PVCs
The incidence, frequency, and complexity of ventricular
arrhythmias were greater in the presence of known or sus-
Journal of
Lifestyle
Medicine
2. 27
Min-Soo Ahn : Current Concepts of Premature Ventricular Contractions
Fig. 1. Example of premature ventricular complex.
Fig. 2. 6-month survival of patients by premature ventricular contractions (PVCs) per hour. Adapted from Maggioni et al [9].
pected heart disease. PVCs and runs of NSVT in subjects
with structural heart disease contribute to an increased mor-
tality risk, the magnitude of which varies with the nature
and extent of the underlying disease.
1. Ischemic heart disease
In 1975, Schulze et al. reported results from the first post-
infarction studies of left ventricular (LV) dysfunction, ven-
tricular arrhythmias, and death that used radionuclide meth-
ods to measure left ventricular ejection fraction (LVEF)
and 24 hr electrocardiogram (ECGs) to assess ventricular
arrhythmias. All eight deaths in their 81 patients occurred
in the group with high-grade ventricular arrhythmias and
LVEF below 40% [6,7]. In a multicenter postmyocardial in-
farction study, 766 patients with acute myocardial in-
farction had their LVEFs measured by radionuclide methods
3. 28
Journal of Lifestyle Medicine Vol. 3, No. 1, March 2013
and a 24 hr ECG analyzed by sensitive and specific
methods. Out of these 766 patients, 86 deaths occurred dur-
ing the 3 year follow-up period. When the variables were
analyzed separately, there were strong associations between
death and LVEF, frequency of VPCs, or repetitiveness of
VPCs [8]. In the GISSI trial, Twenty-four-hour Holter re-
cordings obtained before discharge from the hospital in
8,676 post-myocardial infarction patients were analyzed for
the presence of ventricular arrhythmias. The presence of
more than 10 PVBs per hour or of complex ventricular
arrhythmias was significantly associated with a higher
mortality risk regardless of the presence of LV dysfunc-
tion (Fig. 2) [9]. In December 1990, investigators initiated
prophylactic Multicenter Automatic Defibrillator Implantation
Trial (MADIT) in which high-risk patients with coronary
heart disease and asymptomatic unsustained ventricular ta-
chycardia (a run of 3 to 30 ventricular ectopic beats at a
rate>120 beats per minute) were randomly assigned to re-
ceive an implantable cardioverter defibrillator (ICD) or con-
ventional medical therapy. The prophylactic therapy with
an implanted defibrillator led to improved survival as com-
pared with conventional medical therapy [10]. The
Multicenter Unsustained Tachycardia Trial was initiated in
1989 to test the hypothesis that antiarrhythmic therapy
guided by electrophysiologic testing can reduce the risks of
sudden death and cardiac arrest among patients with coro-
nary artery disease, LV dysfunction, and spontaneous
NSVT. The results of this study established that high risk
patients with asymptomatic, NSVT, and inducible sustained
ventricular tachyarrhythmia have substantial mortality due
to arrhythmia. The rate of death among patients with in-
ducible sustained tachyarrhythmia was reduced by the use
of defibrillators [11]. ICD therapy is indicated in patients
with NSVT due to prior myocardial infarction, LVEF less
than or equal to 40%, and inducible ventricular fibrillation
or sustained VT at electrophysiological study [12].
2. Heart failure
Although we might expect all patients with LV dysfunc-
tion to die from progressive heart failure, many die sud-
denly and unexpectedly without any evidence of recent he-
modynamic or functional deterioration. Sudden death is the
final event in approximately 35-50% of patients with chron-
ic heart failure [13]. The patient with chronic heart failure
is not only at risk of sudden death but is also likely to mani-
fest serious ventricular arrhythmias. In addition to their he-
modynamic derangements, patients with chronic heart fail-
ure have numerous electrical abnormalities that develop and
progress in parallel with the mechanical dysfunction. The
prevalence and complexity of ambulatory ventricular ar-
rhythmias increase dramatically as LV function deteriorates
[14]. In patients with a LVEF of less than 40%, the preva-
lence of NSVT rises from 15-20% in patients with class I-II
symptoms of heart failure to 40-55% in class II-III patients
and 50-70% in class III-IV patients [15]. Numerous studies
have shown an independent direct relationship of complex
cardiac arrhythmias (repetitive forms) and LV dysfunction
with subsequent mortality [16-18]. But in the CHF STAT
study, NSVT was frequently seen in patients with heart fail-
ure and was associated with worsened survival by univariate
analysis. However, after adjusting other variables, especially
for EF, NSVT was not an independent predictor of all-cause
mortality or sudden death. The suppression of NSVT by
amiodarone had no effect on total survival nor on sudden
cardiac death [19]. The Prospective Randomized Milrinone
Survival Evaluation (PROMISE) study was undertaken to
determine whether ventricular arrhythmias were indepen-
dent and specific predictors of sudden death. In this study,
ventricular arrhythmias did not specifically define a group
at high risk for sudden death and did not provide significant
incremental prognostic information beyond readily available
clinical variables (Fig. 3) [20]. The presence of complex
ventricular arrhythmias (especially NSVT) on ambulatory
monitoring predicts total cardiac mortality but does not
identify patients who are destined to die suddenly. This ob-
servation suggests that the frequency and complexity of
rhythm disturbances in patients with severe heart failure re-
flect the severity of the underlying disease process rather
than a specific arrhythmogenic state. NSVT should not guide
therapeutic interventions, such as the institution of antiar-
rhythmic therapy or implantation of antifibrillatory devices.
3. Premature ventricular complexes in the absence
of heart disease
In the Tecumseh, Michigan, communitywide cardiova-
scular epidemiology study, PVCs in subjects with structur-
4. 29
Min-Soo Ahn : Current Concepts of Premature Ventricular Contractions
Fig. 3. ROC curves of multivariate logistic regression models.
Multivariate model including only clinical variables (age, NYHA
class, ejection fraction, systolic blood pressure, cause of heart
failure, and treatment group) is denoted by solid line, whereas
model including number of episodes of NSVT in addition to
clinical variables is denoted by dashed line. Adapted from
Teerlink et al [20].
ally normal hearts carried no adverse prognostic significance
under the age of 30 years, but in those older than 30 years,
PVCs and short runs of NSVT began to influence risk [21].
More recent studies provide conflicting implications regard-
ing risk in asymptomatic subjects. In one study [22], asymp-
tomatic ventricular arrhythmias in the absence of identifi-
able heart disease predicted a small increase in risk, while
another study [23] suggested no increased risk. In 1985,
Kennedy et al. published a follow-up study (mean 6.5
years) of 73 apparently healthy subjects with frequent and
complex ventricular ectopy. The conclusion was that the
long-term prognosis of these patients is similar to that of
the healthy population [2]. In another study, patients with
a diagnosis of idiopathic right ventricular ectopy were eval-
uated after a follow-up of at least 12 years to verify the
occurrence of sudden death and the possible evolution to-
wards arrhythmogenic right ventricular dysplasia (ARVD).
That study reported that no patient developed ARVD, none
died suddenly nor had sustained ventricular tachycardia
during 12 to 20 years follow up for 61 patients.
In contrast to the apparently non-life-threatening im-
plication of PVCs at rest, PVCs elicited during exercise test-
ing, even in apparently normal individuals, appear to imply
risk over time. In the study by Jouven et., a total of 6,101
asymptomatic French men free of clinically detectable car-
diovascular disease were exercised and persons with fre-
quent VPCs, defined as having >10% of all ventricular de-
polarisations in any 30s recordings during exercise, were
found to have an increase in cardiovascular deaths by a fac-
tor of 2.67 after 23 years of follow up [24]. A recently pub-
lished study in 2885 subjects who are offspring of the origi-
nal Framingham study participants also presented similar
findings [25]. A study by Frolkis et al. focused on the re-
covery period of the exercise test and showed that frequent
PVCs during recovery were associated with an increased risk
of death (hazard ratio 2.4) than frequent PVCs during ex-
ercise (hazard ratio 1.8) during a mean of 5.3 years of fol-
low-up [26]. A selection bias, based on indications for stress
testing, may have influenced these observations. Although
additional corroborative data are required from large cohort
studies, these results have prompted the suggestion that fre-
quent VPCs associated with exercise testing be considered
as a new prognostic criterion in addition to ischemia.
PREMATURE VENTRICULAR
CONTRACTION-INDUCED
CARDIOMYOPATHY
Traditionally, PVCs have been thought to be relatively
benign in the absence of structural heart disease [2,5]. Over
the last decade, however, PVC-induced CMP has been a
subject of great interest and the evidence for this entity is
rapidly emerging. The concept of PVC-induced CMP was
proposed by Duffee et al. in 1998 when pharmacological
suppression of PVCs in patients with presumed idiopathic
dilated CMP subsequently improved LV systolic dysfunction
[27]. The exact prevalence of PVC-induced CMP is not
known; it is an underappreciated cause of LV dysfunction,
and it is primarily observed in older patients [28]. Niwano
et al. demonstrated progressive worsening of LV function
in patients with frequent PVCs (>1,000 beats/day) as
measured by the LVEF and LV end-diastolic dimension
over a follow-up period of 4 to 8 years (Fig. 4) [29].
Yarlagadda et al. reported the results of repetitive mono-
morphic ventricular ectopy ablation in 27 patients. In that
study, the ventricular function improved in 7 of 8 patients
5. 30
Journal of Lifestyle Medicine Vol. 3, No. 1, March 2013
Fig. 4. Relationship between the premature ventricular contraction prevalence and change in left ventricular ejection fraction (ΔLVEF)
and left ventricular diastolic dimension (ΔLVEDd). Adapted from Niwano et al [29].
with depressed ventricular function [28].
1. Risk factors for PVCs induced cardiomyopathy
1) PVC burden: Several studies have shown that the fre-
quency of PVCs correlates at least modestly with the extent
of LV dysfunction and ventricular dilation at the time of
initial clinical presentation [29-33]. However, there are no
clear-cut points that mark the frequency at which CMP is
unavoidable. Baman et al. suggested that a PVC burden of
>24% had a sensitivity and specificity of 79% and 78%,
respectively, in separating the patient populations with im-
paired versus preserved LV function [34]. But in another
study, the threshold burden of PVCs for reduced LVEF dif-
fered between those with a LV and those with a RV site
of origin of PVCs. PVCs originating from the RV were as-
sociated with a significantly increased prevalence of reduced
LVEF at a PVC burden ≥10%, whereas PVCs originating
from the LV were associated with reduced LVEF only at
a PVC burden ≥20% [35]. In the MOST trial, ventricular
pacing in the DDDR mode >40% of the time conferred a
2.6-fold increased risk of heart failure hospitalization com-
pared with less pacing. This provided some evidence that
highly paced patients are not only at greater risk for heart
failure hospitalization but are also hospitalized for heart
failure more often [36]. Even though the burden of PVCs
seems to be an important determinant of LV systolic dys-
function, some patients with a high PVC burden do not de-
velop CMP. This suggests that in addition to the PVC bur-
den, other characteristics of PVCs might also be contrib-
utory [37].
2) PVC origin, morphology and duration: Theoreti-
cally, PVC originating in the right ventricle can cause more
severe LV dyssynchrony compared with that originating in
left ventricle and PVC duration also affects the LV
synchronization. The morphology can, to some extent, de-
termine the site and etiology of the PVCs. Munoz et al. ret-
rospectively studied 70 subjects who underwent PVC
ablation. They did not find any association of LVEF with
PVC coupling interval, delay in PVC ID, LBBB versus
RBBB morphology of the PVC or the site of PVC origin,
except for fascicular PVCs. They only reported that PVCs
originating in the RV were associated with reduced LVEF
at a lower threshold PVC burden than that for LV PVCs
as described above [35]. In some recent studies, longer PVC
QRS duration was also associated with the presence of CMP.
However, in a subgroup of patients with very wide PVCs
(mean QRS duration 173 ms), successful suppression of
PVCs failed to normalize LV function [38,39].
6. 31
Min-Soo Ahn : Current Concepts of Premature Ventricular Contractions
2. Mechanism of PVC induced cardiomyopathy
The mechanism of PVC-CMP is presumed to be related
to PVC-induced LV dyssynchrony. Indeed, every known
mechanism of LV dyssynchrony (left bundle branch block,
right ventricular pacing, and preexcitation) can produce CMP
[40,41]. Although QRS duration is a major determinant of
LV dyssynchrony, significant variation in LV activation
patterns and degree of dyssynchrony exists between various
wide QRS morphologies [42]. To predict the future develop-
ment of PVC-CMP, methods of direct LV dyssynchrony as-
sessment during PVC might be required. Additional factors
such as dyssynchrony-induced papillary muscle dysfunction
that can cause mitral regurgitation with additional LV vol-
ume overload, and autonomic response modification by var-
iations in ventriculoatrial conduction, can affect CMP de-
velopment and have not been studied systematically [43,44].
TREATMENT OF PVCs
When considering the need for further intervention and
planning treatment for patients with VPCs, it is important
to consider: (1) whether there is underlying heart disease;
(2) the frequency of the VPCs and if VT has been docu-
mented; and (3) the frequency and severity of symptoms.
In the absence of heart disease and if VPCs are infrequent
or reduce in frequency on exercise tolerance test, with no
documented VT, patients should be reassured and no specif-
ic treatment is required-especially if they are relatively
asymptomatic. The same patients with significant symptoms
should have their blood pressure checked and investigated
and treated if high. β-blockers may be used to control
symptoms in patients where VPCs arise from multiple sites.
It should also be considered in patients with impaired ven-
tricular systolic function and/or heart failure. There is no
evidence to support the use of other antiarrhythmic agents
simply for the sake of suppressing VPCs, especially consid-
ering their proarrhythmic (for example, flecainide) and oth-
er side effects (for example, amiodarone) [45]. A ther-
apeutic medical trial or catheter ablation may be considered
in patients with LV dysfunction and frequent PVCs (a gen-
erally accepted range of >10,000-20,000 or >10% of total
heart beats over 24 hours) if the clinical suspicion for
PVC-induced CMP is high [29,33-35,46].
CONCLUSION
PVCs are early depolarizations of the myocardium origi-
nating in the ventricle. PVCs are frequently observed in the
general population. Traditionally, they have been thought to
be relatively benign in the absence of structural heart dis-
ease but they represent increased risk of sudden death in
structural heart disease. Recently the concept of PVC-in-
duced CMP was proposed when pharmacological suppression
of PVCs in patients with presumed idiopathic dilated CMP
subsequently improved LV systolic dysfunction. The fre-
quency of PVCs correlates at least modestly with the extent
of LV dysfunction and ventricular dilation.
For the treatment PVCs, it is important to consider under-
lying heart disease, the frequency of the PVCs and the fre-
quency and severity of symptoms. Usually asymptomatic
PVCs do not need treatment. In case of symptomatic PVCs,
β-blockers may be used to control the symptoms. A ther-
apeutic medical trial or catheter ablation may be considered
in patients with PVC-induced CMP.
REFERENCES
1. Ng GA. Treating patients with ventricular ectopic
beats. Heart 2006;92:1707-12.
2. Kennedy HL, Whitlock JA, Sprague MK, Kennedy LJ,
Buckingham TA, Goldberg RJ. Long-term follow-up of
asymptomatic healthy subjects with frequent and com-
plex ventricular ectopy. N Engl J Med 1985;312:193-7.
3. Messineo FC. Ventricular ectopic activity: prevalence
and risk. Am J Cardiol 1989;64:53J-6J.
4. Kostis JB, McCrone K, Moreyra AE, Gotzoyannis S,
Aglitz NM, Natarajan N, Kuo PT. Premature ven-
tricular complexes in the absence of identifiable heart
disease. Circulation 1981;63:1351-6.
5. Gaita F, Giustetto C, Di Donna P, Richiardi E, Libero
L, Brusin MC, Molinari G, Trevi G. Long-term follow-up
of right ventricular monomorphic extrasystoles. J Am
Coll Cardiol 2001;38:364-70.
6. Schulze RA Jr, Strauss HW, Pitt B. Sudden death in
the year following myocardial infarction. Relation to
ventricular premature contractions in the late hospitals
phase and left ventricular ejection fraction. Am J Med
1977;62:192-9.
7. Schulze RA Jr, Rouleau J, Rigo P, Bowers S, Strauss
7. 32
Journal of Lifestyle Medicine Vol. 3, No. 1, March 2013
HW, Pitt B. Ventricular arrhythmias in the late hospital
phase of acute myocardial infarction. Relation to left
ventricular function detected by gated cardiac blood
pool scanning. Circulation 1975;52:1006-11.
8. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky
LM. The relationships among ventricular arrhythmias,
left ventricular dysfunction, and mortality in the 2 years
after myocardial infarction. Circulation 1984;69:250-8.
9. Maggioni AP, Zuanetti G, Franzosi MG, Rovelli F,
Santoro E, Staszewsky L, Tavazzi L, Tognoni G. Preva-
lence and prognostic significance of ventricular arrhy-
thmias after acute myocardial infarction in the fi-
brinolytic era. GISSI-2 results. Circulation 1993;87:
312-22.
10. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins
SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber
D, Brown MW, Heo M. Improved survival with an im-
planted defibrillator in patients with coronary disease
at high risk for ventricular arrhythmia. Multicenter
automatic defibrillator implantation trial investigators.
N Engl J Med 1996;335:1933-40.
11. Buxton AE, Lee KL, Fisher JD, Josephson ME,
Prystowsky EN, Hafley G. A randomized study of the
prevention of sudden death in patients with coronary
artery disease. Multicenter unsustained tachycardia
trial investigators. N Engl J Med 1999;341:1882-90.
12. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA,
3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos
G, Hammill SC, Hayes DL, Hlatky MA, Newby LK,
Page RL, Schoenfeld MH, Silka MJ, et al. ACC/AHA/
HRS 2008 guidelines for device-based therapy of cardiac
rhythm abnormalities: executive summary. Heart Rhythm
2008;5:934-55.
13. Packer M. Sudden unexpected death in patients with
congestive heart failure: a second frontier. Circulation
1985;72:681-5.
14. Califf RM, McKinnis RA, Burks J, Lee KL, Harrell
FE Jr, Behar VS, Pryor DB, Wagner GS, Rosati RA.
Prognostic implications of ventricular arrhythmias dur-
ing 24 hour ambulatory monitoring in patients under-
going cardiac catheterization for coronary artery
disease. Am J Cardiol 1982;50:23-31.
15. Kjekshus J. Arrhythmias and mortality in congestive
heart failure. Am J Cardiol 1990;65:42I-8I.
16. Meinertz T, Hofmann T, Kasper W, Treese N, Bechtold
H, Stienen U, Pop T, Leitner ER, Andresen D, Meyer
J. Significance of ventricular arrhythmias in idiopathic
dilated cardiomyopathy. Am J Cardiol 1984;53:902-7.
17. Holmes J, Kubo SH, Cody RJ, Kligfield P. Arrhythmias
in ischemic and nonischemic dilated cardiomyopathy:
prediction of mortality by ambulatory electrocardio-
graphy. Am J Cardiol 1985;55:146-51.
18. Unverferth DV, Magorien RD, Moeschberger ML,
Baker PB, Fetters JK, Leier CV. Factors influencing
the one-year mortality of dilated cardiomyopathy. Am
J Cardiol 1984;54:147-52.
19. Singh SN, Fisher SG, Carson PE, Fletcher RD.
Prevalence and significance of nonsustained ventri-
cular tachycardia in patients with premature ven-
tricular contractions and heart failure treated with vas-
odilator therapy. Department of Veterans Affairs CHF
STAT Investigators. J Am Coll Cardiol 1998;32:942-7.
20. Teerlink JR, Jalaluddin M, Anderson S, Kukin ML,
Eichhorn EJ, Francis G, Packer M, Massie BM.
Ambulatory ventricular arrhythmias in patients with
heart failure do not specifically predict an increased
risk of sudden death. PROMISE (Prospective Rando-
mized Milrinone Survival Evaluation) Investigators.
Circulation 2000;101:40-6.
21. Chiang BN, Perlman LV, Ostrander LD Jr, Epstein
FH. Relationship of premature systoles to coronary
heart disease and sudden death in the Tecumseh epi-
demiologic study. Ann Intern Med 1969;70:1159-66.
22. Bikkina M, Larson MG, Levy D. Prognostic implications
of asymptomatic ventricular arrhythmias: the Framing-
ham Heart Study. Ann Intern Med 1992;117:990-6.
23. Engstrom G, Hedblad B, Janzon L, Juul-Moller S.
Ventricular arrhythmias during 24-h ambulatory ECG
recording: incidence, risk factors and prognosis in men
with and without a history of cardiovascular disease.
J Intern Med 1999;246:363-72.
24. Jouven X, Zureik M, Desnos M, Courbon D, Ducimetiere
P. Long-term outcome in asymptomatic men with ex-
ercise-induced premature ventricular depolarizations.
N Engl J Med 2000;343:826-33.
25. Morshedi-Meibodi A, Evans JC, Levy D, Larson MG,
Vasan RS. Clinical correlates and prognostic significance
of exercise-induced ventricular premature beats in the
community: the Framingham Heart Study. Circulation
2004;109:2417-22.
26. Frolkis JP, Pothier CE, Blackstone EH, Lauer MS.
Frequent ventricular ectopy after exercise as a predictor
of death. N Engl J Med 2003;348:781-90.
27. Duffee DF, Shen WK, Smith HC. Suppression of fre-
quent premature ventricular contractions and improve-
ment of left ventricular function in patients with pre-
sumed idiopathic dilated cardiomyopathy. Mayo Clin
Proc 1998;73:430-3.
28. Yarlagadda RK, Iwai S, Stein KM, Markowitz SM, Shah
BK, Cheung JW, Tan V, Lerman BB, Mittal S. Reversal
of cardiomyopathy in patients with repetitive mono-
morphic ventricular ectopy originating from the right
ventricular outflow tract. Circulation 2005;112:1092-7.
29. Niwano S, Wakisaka Y, Niwano H, Fukaya H,
Kurokawa S, Kiryu M, Hatakeyama Y, Izumi T.
Prognostic significance of frequent premature ven-
8. 33
Min-Soo Ahn : Current Concepts of Premature Ventricular Contractions
tricular contractions originating from the ventricular
outflow tract in patients with normal left ventricular
function. Heart 2009;95:1230-7.
30. Takemoto M, Yoshimura H, Ohba Y, Matsumoto Y,
Yamamoto U, Mohri M, Yamamoto H, Origuchi H.
Radiofrequency catheter ablation of premature ven-
tricular complexes from right ventricular outflow tract
improves left ventricular dilation and clinical status
in patients without structural heart disease. J Am Coll
Cardiol 2005;45:1259-65.
31. Bogun F, Crawford T, Reich S, Koelling TM, Armstrong
W, Good E, Jongnarangsin K, Marine JE, Chugh A,
Pelosi F, Oral H, Morady F. Radiofrequency ablation
of frequent, idiopathic premature ventricular com-
plexes: comparison with a control group without inter-
vention. Heart Rhythm 2007;4:863-7.
32. Taieb JM, Maury P, Shah D, Duparc A, Galinier M,
Delay M, Morice R, Alfares A, Barnay C. Reversal of
dilated cardiomyopathy by the elimination of frequent
left or right premature ventricular contractions. J Interv
Card Electrophysiol 2007;20:9-13.
33. Kanei Y, Friedman M, Ogawa N, Hanon S, Lam P,
Schweitzer P. Frequent premature ventricular com-
plexes originating from the right ventricular outflow
tract are associated with left ventricular dysfunction.
Ann Noninvasive Electrocardiol 2008;13:81-5.
34. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY,
Alguire C, Armstrong W, Good E, Chugh A, Jongnar-
angsin K, Pelosi F Jr, Crawford T, Ebinger M, Oral
H, Morady F, et al. Relationship between burden of
premature ventricular complexes and left ventricular
function. Heart Rhythm 2010;7:865-9.
35. Del Carpio Munoz F, Syed FF, Noheria A, Cha YM,
Friedman PA, Hammill SC, Munger TM, Venkatacha-
lam KL, Shen WK, Packer DL, Asirvatham SJ. Chara-
cteristics of premature ventricular complexes as corre-
lates of reduced left ventricular systolic function: study
of the burden, duration, coupling interval, morphology
and site of origin of PVCs. J Cardiovasc Electrophysiol
2011;22:791-8.
36. Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon
AJ, Freedman RA, Lee KL, Lamas GA. Adverse effect
of ventricular pacing on heart failure and atrial fi-
brillation among patients with normal baseline QRS
duration in a clinical trial of pacemaker therapy for
sinus node dysfunction. Circulation 2003;107:2932-7.
37. Rhee KH, Jung JY, Rhee KS, Kim HS, Chae JK, Kim
WH, Ko JK. Tachycardiomyopathy induced by ven-
tricular premature complexes: complete recovery after
radiofrequency catheter ablation. Korean J Intern Med
2006;21:213-7.
38. Yokokawa M, Kim HM, Good E, Crawford T, Chugh
A, Pelosi F Jr, Jongnarangsin K, Latchamsetty R,
Armstrong W, Alguire C, Oral H, Morady F, Bogun
F. Impact of QRS duration of frequent premature ven-
tricular complexes on the development of cardiomyo-
pathy. Heart Rhythm 2012;9:1460-4.
39. Deyell MW, Park KM, Han Y, Frankel DS, Dixit S,
Cooper JM, Hutchinson MD, Lin D, Garcia F, Bala
R, Riley MP, Gerstenfeld E, Callans DJ, Marchlinski
FE. Predictors of recovery of left ventricular dysfunction
after ablation of frequent ventricular premature depo-
larizations. Heart Rhythm 2012;9:1465-72.
40. van Geldorp IE, Delhaas T, Gebauer RA, Frias P,
Tomaske M, Friedberg MK, Tisma-Dupanovic S, Elders
J, Fruh A, Gabbarini F, Kubus P, Illikova V, Tsao S,
Blank AC, Hiippala A, et al. Impact of the permanent
ventricular pacing site on left ventricular function in
children: a retrospective multicentre survey. Heart
2011;97:2051-5.
41. Udink ten Cate FE, Kruessell MA, Wagner K, Triesch-
mann U, Emmel M, Brockmeier K, Sreeram N. Dilated
cardiomyopathy in children with ventricular pre-
excitation: the location of the accessory pathway is pre-
dictive of this association. J Electrocardiol 2010;43:
146-54.
42. Bleeker GB, Schalij MJ, Molhoek SG, Verwey HF,
Holman ER, Boersma E, Steendijk P, Van Der Wall
EE, Bax JJ. Relationship between QRS duration and
left ventricular dyssynchrony in patients with end-stage
heart failure. J Cardiovasc Electrophysiol 2004;15:544-9.
43. Ypenburg C, Lancellotti P, Tops LF, Boersma E, Bleeker
GB, Holman ER, Thomas JD, Schalij MJ, Pierard LA,
Bax JJ. Mechanism of improvement in mitral regur-
gitation after cardiac resynchronization therapy. Eur
Heart J 2008;29:757-65.
44. Havranek S, Stovicek P, Psenicka M, Wichterle D,
Linhart A. Heart rate turbulence after ventricular pac-
ing trains during programmed ventricular stimulation.
Pacing Clin Electrophysiol 2007;30 Suppl 1:S170-3.
45. Preliminary report: effect of encainide and flecainide
on mortality in a randomized trial of arrhythmia sup-
pression after myocardial infarction. The Cardiac Arrhy-
thmia Suppression Trial (CAST) Investigators. N Engl
J Med 1989;321:406-12.
46. Hasdemir C, Ulucan C, Yavuzgil O, Yuksel A, Kartal
Y, Simsek E, Musayev O, Kayikcioglu M, Payzin S,
Kultursay H, Aydin M, Can LH. Tachycardia-induced
cardiomyopathy in patients with idiopathic ventricular
arrhythmias: the incidence, clinical and electrophy-
siologic characteristics, and the predictors. J Cardiovasc
Electrophysiol 2011;22:663-8.